Medicalgorithmics SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLMDCLG00015
PLN
34.35
0.5 (1.48%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medicalgorithmics SA stock-summary
stock-summary
Medicalgorithmics SA
Pharmaceuticals & Biotechnology
Medicalgorithmics SA is a Poland-based company engaged in the advanced medical equipment and technology industry. The Company develops and manufactures system for the diagnosis of heart arrhythmia. Its product, named PocketECG, is used for remote monitoring of cardiac disorders, arrhythmia diagnosis and monitoring of heart, as well as is used for clinical drugs trials for cardiac safety. In addition, Medicalgorithmics SA provides services in the field of information technology and biotechnology, scientific research and development of natural sciences. Moreover, the Company works on the several projects, such as a device for tele-rehabilitation cardiology, software for optimizing repetitive task in hospitals, as well as devices and systems for remote description of the electrocardiography (ECG). It operates through MEDICALGORITHMICS US HOLDING CORPORATION and Medi-Lynx Cardiac Monitoring LLC and Medi-Lynx Cardiac Monitoring LLC.
Company Coordinates stock-summary
Company Details
Al. Jerozolimskie 81 , WARSZAWA None : 02-001
stock-summary
Tel: 48 22 825124948 697 613020
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michal Wnorowski
Independent Chairman of the Supervisory Board
Mr. Marcin Golebicki
Independent Member of the Supervisory Board
Mr. Artur Malek
Independent Member of the Supervisory Board
Mr. Mariusz Matuszewski
Independent Member of the Supervisory Board
Mr. Marek Tatar
Independent Member of the Supervisory Board
Mr. Krzysztof Urbanowicz
Independent Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Mar 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 338 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.25

stock-summary
Return on Equity

-23.34%

stock-summary
Price to Book

5.13